These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27478193)

  • 1. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776-1784.
    Eur Respir J; 2016 Aug; 48(2):593. PubMed ID: 27478193
    [No Abstract]   [Full Text] [Related]  

  • 2. "Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis." Kevin R. Flaherty, Charlene D. Fell, J. Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L. Stauffer, Frank Gilberg, Monica Bengus and Marlies Wijsenbeek.
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30287496
    [No Abstract]   [Full Text] [Related]  

  • 3. "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis." Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58-64.
    Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324819
    [No Abstract]   [Full Text] [Related]  

  • 4. "Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis." M. Kolb, B. Crestani and T.M. Maher.
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38537950
    [No Abstract]   [Full Text] [Related]  

  • 5. "Desquamative interstitial pneumonia: a systematic review of its features and outcomes." Merel E. Hellemons, Catharina C. Moor, Jan von der Thüsen, Mariska Rossius, Arlette Odink, Laila Haugen Thorgersen, Johny Verschakelen, Wim Wuyts, Marlies S. Wijsenbeek and Elisabeth Bendstrup.
    Eur Respir Rev; 2020 Sep; 29(157):. PubMed ID: 32759375
    [No Abstract]   [Full Text] [Related]  

  • 6. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.
    Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM
    Eur Respir J; 2016 Nov; 48(5):1524-1526. PubMed ID: 27799399
    [No Abstract]   [Full Text] [Related]  

  • 7. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.
    Kawano-Dourado L; Zampieri F; Cavalcanti AB; Damiani LP; Kairalla RA
    Eur Respir J; 2016 Nov; 48(5):1523-1524. PubMed ID: 27799398
    [No Abstract]   [Full Text] [Related]  

  • 8. "Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry." Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh and Tamera J. Corte.
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356377
    [No Abstract]   [Full Text] [Related]  

  • 9. "The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment." Silvia Ulrich and Ekkehard Grunig.
    Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33767003
    [No Abstract]   [Full Text] [Related]  

  • 10. Marlies Wijsenbeek-advocating home monitoring in ILD.
    Kirby T
    Lancet Respir Med; 2023 Jan; 11(1):24-25. PubMed ID: 36206782
    [No Abstract]   [Full Text] [Related]  

  • 11. "Plasma pro-surfactant protein B and lung function decline in smokers." Janice M. Leung, John Mayo, Wan Tan, C. Martin Tammemagi, Geoffrey Liu, Stuart Peacock, Frances A. Shepherd, John Goffin, Glenwood Goss, Garth Nicholas, Alain Tremblay, Michael Johnston, Simon Martel, Francis Laberge, Rick Bhatia, Heidi Roberts, Paul Burrowes, Daria Manos, Lori Stewart, Jean M. Seely, Michel Gingras, Sergio Pasian, Ming-Sound Tsao, Stephen Lam and Don D. Sin, for the Pan-Canadian Early Lung Cancer Study Group. Eur Respir J 2015; 45: 1037-1045.
    Eur Respir J; 2016 Sep; 48(3):962. PubMed ID: 27581417
    [No Abstract]   [Full Text] [Related]  

  • 12. "Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis." Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol,
    Eur Respir J; 2022 Apr; 59(4):. PubMed ID: 35422427
    [No Abstract]   [Full Text] [Related]  

  • 13. ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis.
    Eur Respir J; 2016 Jun; 47(6):E66. PubMed ID: 27246087
    [No Abstract]   [Full Text] [Related]  

  • 14. "An official European Respiratory Society statement: pulmonary haemodynamics during exercise." Gabor Kovacs, Philippe Herve, Joan Albert Barbera, Ari Chaouat, Denis Chemla, Robin Condliffe, Gilles Garcia, Ekkehard Grünig, Luke Howard, Marc Humbert, Edmund Lau, Pierantonio Laveneziana, Gregory D. Lewis, Robert Naeije, Andrew Peacock, Stephan Rosenkranz, Rajeev Saggar, Silvia Ulrich, Dario Vizza, Anton Vonk Noordegraaf and Horst Olschewski.
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29742061
    [No Abstract]   [Full Text] [Related]  

  • 15. Danger-associated molecular patterns and danger signals in idiopathic pulmonary fibrosis.
    Ellson CD; Dunmore R; Hogaboam CM; Sleeman MA; Murray LA
    Am J Respir Cell Mol Biol; 2014 Aug; 51(2):163-8. PubMed ID: 24749648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Cardiovascular disease and COPD: dangerous liaisons." Klaus F. Rabe, John R. Hurst and Samy Suissa.
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30463874
    [No Abstract]   [Full Text] [Related]  

  • 17. "The therapy of idiopathic pulmonary fibrosis: what is next?" Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi,
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31554706
    [No Abstract]   [Full Text] [Related]  

  • 18. "Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis." Bridget F. Collins and Ganesh Raghu.
    Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31722893
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation.
    Swigris JJ; Brown KK; Make BJ; Wamboldt FS
    Respir Med; 2008 Dec; 102(12):1675-80. PubMed ID: 18848771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis." Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown.
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.